Pulmonary Artery
Denervation (PADN)
Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary artery Intervention technique that uses a specific PADN catheter to deliver radiofrequency energy to the sympathetic nerves In the outer membrane of the pulmonary artery, resulting In the disappearance of the myelin sheath of the nerves and the fusion of the axons, which inhibits sympathetic activity, increases cardiac output, reduces the pressure in the pulmonary artery, inhibits the pathologic remodeling of the pulmonary arteries, improves the patient's exercise endurance and cardiac function, and achieves long term benefits from a single minimally invasive procedure.
Milestone
66+
SCI Impact Factors
7000+
SCl Citations
70M+
Global Patient Coverage
5
FDA Designation
Video
Trial
Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension
Aims: This study aimed to assess the long-term effects of pulmonary artery denervation (PADN) on mortality in patients with pulmonary arterial hypertension (PAH).
A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial
Background: Long-term clinical outcomes after pulmonary artery denervation (PADN) in patients with Group 1 pulmonary arterial hypertension (PAH) have not been reported.
3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension
BACKGROUND Long-term benefits of pulmonary artery denervation (PADN) for patients with combined precapillary and postcapillary pulmonary hypertension (CpcPH) secondary to left heart failure are unknown.
Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial
BACKGROUND: The differential treatment effect of pulmonary artery denervation (PADN) in pulmonary arterial hypertension (PAH) patients with different risk burdens remains unclear. This study aimed to determine the effectiveness of PADN in low vs intermediate-high-risk PAH patients.
Pulmonary Artery Denervation for Pulmonary Arterial Hypertension
BACKGROUND World Health Organization (WHO) group 1 pulmonary arterial hypertension (PAH) is a progressive, debilitating disease. Previous observational studies have demonstrated that pulmonary artery denervation (PADN) reduces pulmonary artery pressures in PAH. However, the safety and effectiveness of PADN have not been established in a randomized trial.
Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension
OBJECTIVES The authors sought to assess the benefits of pulmonary artery denervation (PADN) among combined preand post-capillary pulmonary hypertension (CpcPH) patients in a prospective, randomized, sham-controlled trial.
Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension: Results From a Controlled Before and After Study
Background: Pulmonary arterial hypertension (PAH) is a severe disease. 6-minute walk distance (6MWD) is correlated
Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary
Background—The mechanisms underlying pulmonary arterial hypertension (PAH) are multifactorial. The efficacy of pulmonary artery denervation (PADN) for idiopathic PAH treatment has been evaluated.
Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension
This study was designed to test the safety and efficacy of pulmonary artery (PA) denervation (PADN) for patients with idiopathic PA hypertension (IPAH) not responding optimally to medical therapy.
Cookie Policy · Legal Statement · Privacy Policy
Copyright © 2025 PULNOVO MEDICAL